Insider Transactions in Q1 2023 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,707
-3.71%
|
$795,858
$294.33 P/Share
|
|
Feb 10
2023
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,377
-1.96%
|
$404,838
$294.33 P/Share
|
|
Feb 10
2023
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,611
-3.27%
|
$767,634
$294.33 P/Share
|
|
Feb 10
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
902
-1.34%
|
$265,188
$294.33 P/Share
|
|
Feb 10
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,461
-5.04%
|
$1,017,534
$294.33 P/Share
|
|
Feb 10
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,372
-3.5%
|
$991,368
$294.33 P/Share
|
|
Feb 10
2023
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,707
-3.47%
|
$795,858
$294.33 P/Share
|
|
Feb 10
2023
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,372
-2.13%
|
$991,368
$294.33 P/Share
|
|
Feb 06
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,304
-0.31%
|
$396,416
$304.48 P/Share
|
|
Feb 06
2023
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,304
+1.83%
|
$243,848
$187.53 P/Share
|
|
Feb 02
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
3,578
-4.53%
|
$1,134,226
$317.83 P/Share
|
|
Feb 01
2023
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
BUY
Grant, award, or other acquisition
|
Direct |
24,322
+11.58%
|
-
|
|
Feb 01
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,026
+13.88%
|
-
|
|
Feb 01
2023
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
26,400
+11.06%
|
-
|
|
Feb 01
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
BUY
Grant, award, or other acquisition
|
Direct |
29,272
+14.61%
|
-
|
|
Feb 01
2023
|
Jeffrey M Leiden Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
76,578
+31.09%
|
-
|
|
Feb 01
2023
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
28,452
+12.22%
|
-
|
|
Feb 01
2023
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
68,478
+14.53%
|
-
|
|
Feb 01
2023
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,293
+35.2%
|
-
|
|
Feb 01
2023
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,516
+27.2%
|
-
|
|
Feb 01
2023
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
38,221
+13.35%
|
-
|
|
Feb 01
2023
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,568
+15.83%
|
-
|
|
Jan 31
2023
|
Bruce I Sachs Director |
SELL
Open market or private sale
|
Direct |
1,200
-2.83%
|
$390,000
$325.01 P/Share
|
|
Jan 31
2023
|
Bruce I Sachs Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+2.75%
|
$86,400
$72.14 P/Share
|
|
Jan 31
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
106
-0.28%
|
$34,450
$325.0 P/Share
|
|
Jan 30
2023
|
Lloyd Carney Director |
SELL
Open market or private sale
|
Direct |
2,700
-15.2%
|
$864,000
$320.87 P/Share
|
|
Jan 27
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
1,429
-16.24%
|
$460,138
$322.28 P/Share
|
|
Jan 27
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,429
+30.19%
|
$102,888
$72.14 P/Share
|
|
Jan 26
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
4,000
-17.04%
|
$1,272,000
$318.44 P/Share
|
|
Jan 26
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+40.51%
|
$288,000
$72.14 P/Share
|
|
Jan 25
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
4,000
-29.62%
|
$1,252,000
$313.95 P/Share
|
|
Jan 25
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+40.51%
|
$288,000
$72.14 P/Share
|
|
Jan 25
2023
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
10,000
-10.04%
|
$3,150,000
$315.05 P/Share
|
|
Jan 24
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
4,000
-43.5%
|
$1,248,000
$312.82 P/Share
|
|
Jan 24
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+40.51%
|
$288,000
$72.14 P/Share
|
|
Jan 23
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,129
-53.17%
|
$664,248
$312.02 P/Share
|
|
Jan 23
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,129
+34.71%
|
$153,288
$72.14 P/Share
|
|
Jan 18
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
442
-19.08%
|
$137,904
$312.17 P/Share
|
|
Jan 18
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
442
+16.02%
|
$31,824
$72.14 P/Share
|
|
Jan 17
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
4,000
-68.09%
|
$1,248,000
$312.03 P/Share
|
|
Jan 17
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+40.51%
|
$288,000
$72.14 P/Share
|